Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Atai Life Sciences N.V. ATAI
$1.91
-$0.05 (-2.81%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
326209650.00000000
-
week52high
4.96
-
week52low
1.14
-
Revenue
233000
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-0.94000000
-
Last Dividend
6.82000000
-
Next Earnings Date
24 мар 2023 г. в 11:00
Описание компании
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kirpekar Sahil | A | 750000 | 750000 | 01 дек 2022 г. |
| Smiley Andrea Heslin | A | 64000 | 64000 | 25 мая 2022 г. |
| JOHNSON SABRINA MARTUCCI | A | 64000 | 64000 | 25 мая 2022 г. |
| de Rosnay Alexis | A | 64000 | 64000 | 25 мая 2022 г. |
| Auerbach Michael | A | 64000 | 64000 | 25 мая 2022 г. |
| Angermayer Christian | A | 64000 | 64000 | 25 мая 2022 г. |
| Kalali Amir H | A | 64000 | 64000 | 25 мая 2022 г. |
| Apeiron Investment Group Ltd. | A | 1799302 | 21900 | 29 апр 2022 г. |
| Apeiron Investment Group Ltd. | A | 1777402 | 34700 | 28 апр 2022 г. |
| Apeiron Investment Group Ltd. | A | 1742702 | 19803 | 27 апр 2022 г. |
Новостная лента
The 7 Most Promising Psychedelic Stocks to Buy in February
InvestorPlace
05 февр 2023 г. в 14:30
Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.
Down -34.59% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI)
Zacks Investment Research
31 янв 2023 г. в 11:00
atai Life Sciences N.V. (ATAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
atai Life Sciences N.V. (ATAI) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
18 янв 2023 г. в 13:33
atai Life Sciences N.V. (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Psychedelic Sunday: Competitive Strategies
Seeking Alpha
15 янв 2023 г. в 11:45
Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?
Scrutinizing Psychedelic Stocks
Seeking Alpha
08 янв 2023 г. в 11:30
What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management.